EACH VIAL CONTAINS 5MG OF GHRP 2
Supplied for Research Purposes Only
This information and product is provided for research purposes only. We do not provide any advice on the usage of these products as UK Law prevents this. Customers should check the legality of this product in their own country prior to purchase.
Benefits and uses:
Increased vigour, stamina, and flexibility.
Improvements in surgery recovery and injury healing.
Sleep improvement improves mood and productivity.
A rise in the proportion of lean body mass and a decline in body fat.
Increased muscular mass and quickening of muscle tissue growth.
Calcium retention is increased, bone mineralization is improved, and bone strength is increased.
Promotion of the immune system, overall health, and benefits of anti-aging
Production of IGF-1, which has an anabolic, muscle-building impact.
Increased hypothalamic stimulation improves simultaneous hunger and drive.
150-300 mcg 3 times per day for athletic performance.
150mcg before bed for anti aging purposes.
What is GHRP-2?
Growth Hormone Releasing Peptide-2 (GHRP-2), also known as Pralmorelin, is a synthetic peptide that encourages the body to produce more growth hormone naturally. Ghrelin, a gut peptide also known as "the hunger hormone," is an agonist of GHRP-2, which binds to the growth hormone secretagogue receptor. Growth hormone release and the beginning of appetite have both been demonstrated to be stimulated by ghrelin.
GHRP-2 is utilised to improve flexibility and joint health, as well as to grow muscle mass and lower body fat. Better training and injury rehabilitation are also encouraged by GHRP-2. Additionally, GHRP-2 serves to promote anti-aging advantages, sleep quality, and general health and fitness. Increased levels of growth hormone also cause the body to produce more IGF-1, which improves lean body composition, speeds up the growth of muscle tissue, and lowers body fat. Long-term use of GHRP-2 encourages a significant improvement in strength and endurance. With the administration of this peptide, physical capability, aging-related decline, and athletic performance can all significantly improve.
One of the growth hormone-releasing peptides with the best impact on both athletic performance and anti-aging effects is known as GHRP-2. It encourages significant increases in the body's production of growth hormone while reducing the potent adverse effects of GHRP-6 related to appetite. Lean body composition may significantly improve as a result of this.
Process of Action
There are two ways that GHRP-2 increases the generation of natural growth hormone. First, the GHRP-2 amplifies the signal that naturally releases growth hormone, which causes a significant secretion of growth hormone. Second, it inhibits somatostatin, also known as growth hormone inhibiting hormone, a hormone in the body (GHIH). Somatostatin causes the body to produce less naturally occurring growth hormone. GHRP-2 can enhance the production of growth hormone and hence boost levels of natural growth hormone by limiting the activity of somatostatin. Additionally, the peptide hormone ghrelin, which is produced in the digestive system and has a significant impact on both appetite and the generation of growth hormone, is activated by GHRP-2.
In contrast to when synthetic hGH is administered, GHRP-2 stimulates the body to produce growth hormone, therefore natural growth hormone production is not cut off. Instead of being elevated continuously, GHRP-2 produces growth hormone secretion in a way that closely reflects natural release patterns. With this approach, numerous harmful effects of synthetic hGH administration are avoided, including the cessation of natural growth hormone production.
In most cases, GHRP-2 causes extremely minor adverse effects, if any at all. Ghrelin's better action may cause a modest rise in hunger. Additionally possible side effects include fatigue and lethargy, which can be prevented by taking the medication before bed.
In addition to water retention, excessive GHRP-2 use can cause tingling or numbness in the hands and feet. This can indicate that the dosage has to be lowered because it is too high.
1 Bowers CY. Novel GH releasing peptides. In Molecular and Clinical Advances in Pituitary Disorders. Proceedings of the Third International Pituitary Congress, pp 153–157. Ed S Melmed. Los Angeles: Endocrine Research and Education, 1993.
2 Bowers CY. On a peptidomimetic growth hormone-releasing peptide (Editorial). Journal of Clinical Endocrinology and Metabolism 1994 79 940–942.
3 De Boer H, Blok GJ & Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63– 86.
4 Hartman ML, Farello G, Pezzoli SS & Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. Journal of Clinical Endocrinology and Metabolism 1992 74 1378–1384.
5 Martha Jr PM, Blizzard RM, Mc Donald JA, Thorner MO & Rogol AD. A persistent pattern of varying pituitary responsivity to exogenous growth hormone (GH)-releasing hormone in GHdeficient children: evidence supporting periodic somatostatin secretion. Journal of Clinical Endocrinology and Metabolism 1988 67 449–454.
6 Vance ML, Kaiser DL, Martha Jr PM, Furlanetto R, Rivier J, ValeW et al. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. Journal of Clinical Endocrinology and Metabolism 1989 68 22–28.
7 Vance ML. Growth hormone for the elderly? (Editorial). New England Journal of Medicine 1990 323 52–54.
8 Bowers CY. GH releasing peptides: structure and kinetics. Journal of Pediatric Endocrinology 1993 6 21–31.
9 Ghigo E, Arvat E, Rizzi G, Goffi S, Grottoli S, Mucci M et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. European Journal of Endocrinology 1994 131 499–503.
10 Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E et al. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. Journal of Clinical Endocrinology and Metabolism 1990 71 1481–1485.
11 Corpas E, Harman SM & Blackman MR. Human growth hormone and human aging. Endocrine Reviews 1993 14 20–39.
12 Mu¨ ller EE, Cocchi D, Ghigo E, Arvat E Locatelli V & Camanni F. Growth hormone response to GHRH during lifespan. Journal of Pediatric Endocrinology 1993 6 5–13.
13 Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration inman. Journal of Clinical Endocrinology and Metabolism 1994 78 693–698.
14 Gertz BJ, Barrett JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR et al. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. Journal of Clinical Endocrinology and Metabolism 1993 77 1393–1397.
15 Huhn WC, Hartman ML, Pezzoli SS & Thorner MO. Twenty-fourhour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. Journal of Clinical Endocrinology and Metabolism 1993 76 1202–1208.
16 Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY & Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. Journal of Clinical Endocrinology and Metabolism 1993 77 1641–1647.
17 Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R & Camanni F. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. European Journal of Endocrinology 1996 135 407–412.
18 DeBell WK, Pezzoli SS & Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation. Journal of Clinical Endocrinology and Metabolism 1991 72 1312–1316.
19 Copinschi C, Van Onderbergen A, L’Hermite-Bale´riaux M, Mendel CM, Caufriez A, Leproult L et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hGHprofiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism 1996 81 2776–2782.
20 Strasburger CJ, Wu Z, Pflaum CD & Dressendo¨rfer RA. Immunofunctional assay of human growth hormone (hGH) in serum: a possible consensus for quantitative hGH measurement. Journal of Clinical Endocrinology and Metabolism 1996 81 2613–2620.
21 Iovino M, Monteleone P & Steardo L. Repetitive growth hormonereleasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. Journal of Clinical Endocrinology and Metabolism 1989 69 910–913.
22 Kelly PA, Djiane J, Postel-Vinay MC & Edery M. The prolactin/ growth hormone receptor family. Endocrine Reviews 1991 12 235–251.
23 De Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC & Van der Veen EA. Monitoring of growth hormone replacement therapy in adults, based onmeasurement of serummarkers. Journal of Clinical Endocrinology and Metabolism 1996 81 1371–1377.
24 Blok GJ, Van der Veen EA, Susgaard S & Larsen F. Influence of concentration and injection volume on the bioavailability of subcutaneous growth hormone: comparison of administration by ordinary syringe and by injection pen. Pharmacology and Toxicology 1991 68 355–359.
25 Jørgensen JOL, Moller J, Jenssen FS, Jørgensen JT & Christiansen JS. Growth hormone administration by means of an injection pen. Pharmacology and Toxicology 1989 65 96–99. 400 E A Nijland and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (1998) 139 Downloaded from Bioscientifica.com at 07/26/2022 05:11:11PM via free access
26 Brixen K, Nielsen HK, Mosekilde L & Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. Journal of Bone and Mineral Research 1990 5 609–618.
27 Corpas E, Harman SM, Pin˜ eyro MA, Roberson R & Blackman MR. Growth hormone (GH)-releasing hormone-(1–29) twice daily reverses the decreased GH and insulin-like growth factor-1 levels in old men. Journal of Clinical Endocrinology and Metabolism 1992 75 530–535.
28 Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS & Thorner MO. Growth hormone (GH)-releasing peptide stimulate GH release in normal men and acts synergistically with GHreleasing hormone. Journal of Clinical Endocrinology and Metabolism 1990 70 975–982.
29 Jørgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KGMM, Ørskov H & Christiansen JS. Dose–response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 1988 67 36–40.
30 Jørgensen JOL, Blum WF, Moller N, Ranke MB & Christiansen JS. Short-term changes in serum insulin-like growth-factors (IGF) and IGF binding protein after different modes on intravenous growth hormone (GH) exposure in GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 1990 72 582–587.
31 Jørgensen JOL, Moller N, Lauritzen T & Christiansen JS. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulinlike growth factor-I and metabolic indices. Journal of Clinical Endocrinology and Metabolism 1990 70 1616–1623.